Guest Editorials

Apolipoprotein E and Functional Illness in the Elderly

Following on from the hypothesis of a role for the ApoE ε4 and ε2 alleles as risk and protective factors, respectively, for late-onset Alzheimer’s disease (AD) came inevitable questions regarding other psychiatric conditions of late onset including depressive illness and schizophrenia. Is ApoE ε4 a risk factor in these diseases and do carriers have an earlier age of onset? Does ApoE ε2 have a protective role, with carriers of this allele having a later age of onset?

Studies (Forsell et al., 1997; Holmes et al., 1998; Zubenko et al., 1996) comparing ApoE allele frequencies in depressed aged subjects across differing ages of onset with frequencies in age-matched controls have found little evidence that carriers of the ApoE ε4 allele have an increased risk of developing depressive illness or have an earlier age of onset, but have found some, albeit modest, evidence that carriers of the ApoE ε2 allele are offered some protection from the disease with a delayed onset. Studies of ApoE allele frequencies in subjects with late-onset (over the age of 45 years) depressive illness have been inconclusive; one early study (Krishnan et al., 1996) showed evidence for an increased frequency of the ApoE ε4 allele in the late-onset group compared with both the early-onset group and controls, but another study (Heidrich et al., 1997) found no such evidence. However, none of these studies have reported on age-of-onset effects of ApoE alleles in the late-onset group alone.

In regard to schizophrenia, an initial early report suggesting a positive association between the presence of the ApoE ε4 allele and schizophrenia (Harrington et al., 1995) has been refuted by more recent studies showing no association (Arnold et al., 1997; Jönsson et al., 1996; Joober et al., 1996; Kimura et al., 1997; Powchik et al., 1997; Town et al., 1997; Zhu et al., 1996). Some of these studies have also looked at age of onset, with two reports (Kimura et al., 1997; Zhu et al., 1996) showing no association between carriers of the ApoE ε4 allele and age of onset and one report (Arnold et al., 1997) showing ApoE ε4 carriers to have an earlier onset. In keeping with this finding, one study (Howard et al., 1995) of patients with late-onset (over the age of 60 years) schizophrenia showed a low frequency of the ApoE ε4 allele compared with published data in controls.

In AD, the situation regarding coexistent functional illness and ApoE is even more complicated. Although an early study found a positive association between carriers of the ApoE ε4 allele and depressive illness (Ramachandran et al., 1996), later studies showed either no association
(Holmes et al., 1996; Lopez et al., 1997) or a negative association between carriers of the ApoE ε4 allele and depressive illness (Ballard et al., 1997; Cantillon et al., 1997; Lyketos et al., 1997) and a positive association between carriers of the ApoE ε2 allele and depressive symptoms (Holmes, 1996). Likewise the association between carriers of the ApoE ε4 allele and psychosis has been found in some (Ballard et al., 1997; Holmes, 1997; Ramachandran et al., 1996) but not all studies (Lopez et al., 1997; Lyketos et al., 1997).

Trying to make sense of these findings is not helped by the different approaches to the important issue of age of onset. Some studies group all aged subjects together with no age-of-onset division and others divide depressive illness and schizophrenia, in an analogous fashion to AD, into early and late illness based upon an often arbitrary dividing point. Both approaches have their faults. Grouping all subjects together is dangerous if genetic heterogeneity exists, and an emphasis on a rigid dividing point presupposes knowledge of genetic subgroups based on age of onset, which we do not yet possess. It is worth remembering that the assumption of genetic homogeneity in early-onset AD led to considerable confusion in early studies of this disease and that the age-of-onset effects of ApoE ε4 are largely restricted to late-onset AD.

However, even taking these points into consideration, it is clear that ApoE does not have a major role to play in depressive illness or schizophrenia when they are considered as homogeneous groups. On the other hand, contradictory reports regarding age-of-onset effects of both the ApoE ε2 and ApoE ε4 alleles in depressive illness and schizophrenia and the lack of large studies of subjects with late-onset illness make it premature to rule out age-of-onset effects of these alleles in specific subgroups.

Is it possible to reconcile the associations found between ApoE status and late-onset functional illness with those found between ApoE status and functional illness in AD? In depressive illness, clinical genetic studies may offer some clues. First, depressive illness occurring for the first time in AD subjects has been associated with a greater frequency of depressive illness in first-degree relatives but not with a familial liability for dementia (Pearlson et al., 1990; Strauss et al., 1996). Second, late-onset depressive illness does not interact with ApoE ε4 to increase the relative risk of developing AD but is a greater risk factor for AD than early-onset depressive illness, with increasing risk ratios the shorter the interval between the onset of depression and the onset of AD (Steffens et al., 1997). These findings can be explained if, instead of acting as a simple genetic risk factor for depressive illness, ApoE is considered to be acting as a quantitative trait variable as regards age of onset in a specific subgroup of subjects, namely late-onset depressive illness. Thus if ApoE ε4 hastens and ApoE ε2 delays the age of onset of late-onset depressive illness, then it would be anticipated, as shown in a number of studies (Ballard et al., 1997; Cantillon et al., 1997; Holmes, 1996; Lyketos et al., 1997), that AD patients with depression would have a relatively low frequency of the ApoE ε4 allele or, alternatively, have a greater frequency of the ApoE ε2 allele. Schizophrenia, unlike depressive illness, is less clearly a risk factor for late-onset AD and there is little evidence to show that increasing age of onset is associated with a greater risk of developing AD.
Thus the relationship between ApoE, late-onset schizophrenia, and psychosis in AD is less clear, but it seems unlikely that a similar mechanism to that proposed above is operating here.

Regardless of whether ApoE will give some insight into the relationship between functional illness and noncognitive symptoms in AD, it is clear that if ApoE does have an age-of-onset effect in depressive illness and schizophrenia, then some insight will be gained into the role that ApoE plays in cell biology. Thus, neither depressive illness nor schizophrenia is associated with the hallmarks of AD, namely, increased deposition of amyloid or tangle formation. This makes it unlikely that ApoE acts as a direct risk factor for AD, but suggests that ApoE has a more general role to play. Future research might thus be more profitably spent by evaluating more closely the normal role of ApoE in the central nervous system.

REFERENCES


Medical Genetics (Neuropsychiatric Genetics), 67, 235.


Clive Holmes, BSc, MRCPsych
The Maudsley
Institute of Psychiatry
London, England

International Psychogeriatrics, 10(1), March 1998